Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 3, 2015, Pages 632-641

  Fattom, Ali ^a   Matalon, Albert ^b   Buerkert, John ^c   Taylor, Kimberly ^d   Damaso, Silvia ^e   Boutriau, Dominique ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia Nephrology ^*  (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e GSK   (Belgium)

Author keywords

End stage renal disease; Hemodialysis; Immunogenicity; Staphylococcus aureus; Vaccine; Vaccine safety

Indexed keywords

PLACEBO; STAPHYLOCOCCUS VACCINE; BACTERIUM ANTIBODY; VACCINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FEMALE; HEART ARREST; HEART DISEASE; HEMODIALYSIS; HUMAN; INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; VACCINE FAILURE; VACCINE PRODUCTION; ADOLESCENT; ADVERSE EFFECTS; BACTEREMIA; BLOOD; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INCIDENCE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BACTEREMIA; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84928676653     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34414     Document Type: Article

References (38)

1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. Antimicrobial- resistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14; PMID:23221186; http://dx.doi.org/10.1086/668770.
2. Vandecasteele SJ, Boelaert JR, De Vriese AS. Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol 2009; 4:1388-400; PMID:19590063; http://dx.doi.org/10.2215/CJN.01590309.
3. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3:1526-33; PMID:18701615; http://dx.doi.org/10.2215/CJN.00950208.
4. Chan KE, Warren HS, Thadhani RI, Steele DJR, Hymes JL, Maddux FW, Hakim RM. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23:1551-9; PMID:22904350; http://dx.doi.org/10.1681/ASN.2012010050.
5. Li Y, Friedman JY, O'Neal BF, Hohenboken MJ, Griffiths RI, Stryjewski ME, Middleton JP, Schulman KA, Inrig JK, Fowler VG Jr, et al. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol 2009; 4:428-34; PMID:19118117; http://dx.doi.org/10.2215/CJN03760708.
6. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, Lynfield R, Dumyati G, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304:641-8; PMID:20699455.
7. Fitzgerald SF, O'Gorman J, Morris-Downes MM, Crowley RK, Donlon S, Bajwa R, Smyth EG, Fitzpatrick F, Conlon PJ, Humphreys H. A 12-year review of Staphylococcus aureus bloodstream infections in haemodialysis patients: more work to be done. J Hosp Infect 2011; 79:218-21; PMID:21856042; http://dx.doi.org/10.1016/j.jhin.2011.06.015.
8. Moist LM, Trpeski L, Na Y, Lok CE. Increased hemodialysis catheter use in Canada and associated mortality risk: data from the Canadian Organ Replacement Registry 2001-2004. Clin J Am Soc Nephrol 2008; 3:1726-32; PMID:18922993; http://dx.doi.org/10.2215/CJN.01240308.
9. Crowley L, Wilson J, Guy R, Pitcher D, Fluck R. Chapter 12 Epidemiology of Staphylococcus aureus bacteraemia amongst patients receiving dialysis for established renal failure in England in 2009 to 2011: a joint report from the Health Protection Agency and the UK Renal Registry. Nephron Clin Pract 2012; 120 (Suppl 1):233-45; PMID:22964570; http://dx.doi.org/10.1159/000342856.
10. Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membranedamaging virulence factors? Front Cell Infect Microbiol 2012; 2:12; PMID:22919604.
11. Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 2009; 23:153-71; PMID:19135920; http://dx.doi.org/10.1016/j.idc.2008.10.005.
12. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine 2012; 30:2921-7; PMID:22115633; http://dx.doi.org/10.1016/j.vaccine.2011.11.006.
13. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013; 309:1368-78; PMID:23549582; http://dx.doi.org/10.1001/jama.2013.3010.
14. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17:218-34; PMID:14726462http://dx.doi.org/10.1128/CMR.17.1.218-234.2004.
15. Von Eiff, C, Taylor KL, Mellmann A, Fattom AI, Friedrich AW, Peters G, Becker K. Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus. Diagn Microbiol Infect Dis 2007; 58:297-302; PMID:17376630; http://dx.doi.org/10.1016/j.diagmicrobio.2007.01.016.
16. Roghmann M, Taylor KL, Gupte A, Zhan M, Johnson JA, Cross A, Edelman R, Fattom AI. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. J Hosp Infect 2005; 59:27-32; PMID:15571850; http://dx.doi.org/10.1016/j.jhin.2004.07.014.
17. Verdier I, Durand G, Bes M, Taylor KL, Lina G, Vandenesch F, Fattom AI, Etienne J. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J Clin Microbiol 2007; 45:725-9; PMID:17202275; http://dx.doi.org/10.1128/JCM.01572-06.
18. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6; PMID:11844850; http://dx.doi.org/10.1056/NEJMoa011297.
19. Sutter D, Summers A, Keys C, Taylor KL, Frasch C, Braun L, Fattom A, Bash M. Capsular serotype of Staphylococcus aureus in the era of communityacquired MRSA. FEMS Immunol Med Microbiol 2011; 63:16-24; PMID:21631600; http://dx.doi.org/10.1111/j.1574-695X.2011.00822.x.
20. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20:440-51; PMID:17897251; http://dx.doi.org/10.1111/j.1525-139X.2007.00283.x.
21. Litjens NHR, Huisman M, van den Dorpel M,, Betjes MG. Impaired immune responses and antigen-specific memory CD4C T cells in hemodialysis patients. J Am Soc Nephrol 2008; 19:1483-90; PMID:18480314; http://dx.doi.org/10.1681/ASN.2007090971.
22. Agrawal S, Gollapudi P, Elahimehr R, Pahl MV, Vaziri ND. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant 2010; 25:737-46; PMID:19903659; http://dx.doi.org/10.1093/ndt/gfp580.
23. Creech CB 2nd, Johnson BG, Alsentzer AR, Hohenboken M, Edwards KM, Talbot TR 3rd. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine 2009; 28:256-60; PMID:19799842; http://dx.doi.org/10.1016/j.vaccine.2009.09.088.
24. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 2005; 73:3502-11; PMID:15908379; http://dx.doi.org/10.1128/IAI.73.6.3502-3511.2005.
25. Lu T, Porter AR, Kennedy AD, Kobayashi SD, Deleo FR. Phagocytosis and killing of Staphylococcus aureus by human neutrophils. Infection and Immunity 2014; PMID:24713863.
26. Cheung GYC, Otto M. The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections. Expert Opin Ther Targets 2012; 16:601-12; PMID:22530584; http://dx.doi.org/10.1517/14728222.2012.682573.
27. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, Allantaz F, Pascual V, Banchereau J, Chaussabel D, Ramilo O. Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS ONE 2009; 4:e5446; PMID:19424507; http://dx.doi.org/10.1371/journal.pone.0005446.
28. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-7; PMID:22186773; http://dx.doi.org/10.1093/cid/cir828.
29. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE Jr, Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5: e1000703; PMID:20041174http://dx.doi.org/10.1371/journal.ppat.1000703.
30. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80; PMID:18644876; http://dx.doi.org/10.1128/IAI.00700-08.
31. Wang J, Roderiquez G, Norcross MA. Control of adaptive immune responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2. Sci Rep 2012; 2:606; PMID:22930672.
32. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012; 15:92-9; PMID:22088393; http://dx.doi.org/10.1016/j.mib.2011.10.012.
33. Lalani T, Tribble D, Landrum M, Stewart S, Niknian M, Fattom A, Fraser J, Wilkins K, Kessler P, Fahim R, et al. Neutralizing activity of antibodies following vaccination with Staphylococcus aureus recombinant a-toxoid (rAT) and recombinant Panton-Valentine Leukocidin toxoid (rLukS-PV). In: ID Week. San Francisco: 2013.
34. Landrum M, Lalani T, Niknian M, Maguire J, Fraser J, Wilkins K, Ellis M, Kessler P, Fahim R, Tribble D. A randomized, multi-center trial to evaluate the safety and immunogenicity of Staphylococcus aureus toxoids, rAT and rLukS-PV, in healthy volunteers. Boston, MA, USA: 2011.
35. Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990; 58:2367-74; PMID:2114365.
36. Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, Robbins JB, Schneerson R. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect Immun 1992; 60:584-9; PMID:1730492.
37. Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (Staph- VAX) in hemodialysis patients. Vaccine 2004; 23:656-63; PMID:15542186; http://dx.doi.org/10.1016/j.vaccine.2004.06.043.
38. Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998; 5:479-85; PMID:9665952.